938P Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)

C Le Tourneau,C Even,S Salas,Y Pointreau,P Ceruse,E Babin,J Fayette,V Rondeau,V Grumberg,F-E Cotté,A Govart,K Baumstarck,J Guigay

doi:10.1016/j.annonc.2023.09.2082

938P Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)

C Le Tourneau, C Even + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.2082

Copy DOI

Journal: Annals of Oncology

Publication Date: Oct 1, 2023

Affiliation: Institut Gustave Roussy, Aix-Marseille University, Centre Jean Bernard, Hospices Civils de Lyon, Université de Caen Normandie, Normandie Université, Centre Léon Bérard, Bordeaux Population Health, Inserm, University of Bordeaux, Bristol-Myers Squibb (France), Groupe d'Oncologie Radiothérapie Tête et Cou

#Squamous Cell Carcinoma Of Head #Real-world Effectiveness + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

938P Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.